Skip to content
Screener

Axsome Therapeutics AXSM Q2 2025 earnings

Reported August 4, 2025 · Before market open

Revenue$150.0MBeat by $10.0M
EPS-$0.92Beat by $0.08
Revenue estimate$140.0M
EPS estimate-$1.00

Next report

Nov 2, 2026 (in a month)
Revenue estimate$258.3M
EPS estimate-$0.49

Financials

Q2 2025

Income statement

See full
Revenue$150.0M+72.1%
Gross profit$136.6M+72.7%
Operating income-$36.7M+53.0%
Net income-$48.0M+39.5%
EPS (diluted)-$0.97+41.9%

Balance sheet

See full
Cash & equivalents$303.0M-4.0%
Total debt$217.3M+13.3%
Total equity$73.1M-29.0%
Total assets$639.8M+16.7%

Cash flow

See full
Operating cash flow-$32.4M-7.7%
CapEx$13.0K-75.0%
Free cash flow-$32.4M-7.5%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$5.13B+34.6%
Enterprise value$5.05B+36.7%
P/S10.4×-2.7×

Profitability

See full
Gross margin91.5%+1.2pp
Operating margin-46.2%-16.6pp
Net margin-49.9%-17.3pp
FCF margin-24.5%-8.9pp

Returns & leverage

See full
Return on equity-280.7%+782pp
Debt / equity3×+1.1×
Current ratio1.6×-0.9×

Segments

By product

See full
Royalty$1.1M—
Royalty And Milestone Revenue$1.1M—

FAQ

When did Axsome Therapeutics report Q2 2025 earnings?
Axsome Therapeutics (AXSM) reported Q2 2025 earnings on August 4, 2025 before market open.
What were Axsome Therapeutics's Q2 2025 revenue and EPS?
Axsome Therapeutics reported revenue of $150.0M and eps of $-0.92 for Q2 2025.
Did Axsome Therapeutics beat estimates in Q2 2025?
Revenue beat the consensus estimate of $140.0M by $10.0M. EPS beat the consensus estimate of $-1.00 by $0.08.
How did Axsome Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 72.1% from $87.2M a year earlier and eps grew 25.8% from $-1.24.
Where can I find Axsome Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-101624) and the 10-Q periodic report (0000950170-25-102148) directly on SEC EDGAR. The filing index links above go to sec.gov.